Clinical Trial

Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC

Study acronym: SBS-CEUS
Completed
View on ClinicalTrials.gov →
Summary
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the fourth leading cause of cancer-related deaths worldwide \[1\]. Although surgical resection remains the reference curative therapy, ultrasound-guided microwave ablation (MWA) yields comparable oncologic outcomes \[2,3\] and is endorsed as a first-line option in several national and international guidelines. A sufficient ablative ablation margins (AM) is pivotal for preventing local tumour progression (LTP) \[4,5\]. According to current consensus, technical success is judged one month after ablation using contrast-enhanced CT (CE-CT) or MRI (CE-MRI) together with long-term follow-up \[6,7\]. Yet, inflammatory changes within the ablation zone peak during the first few days, delaying reliable evaluation, increasing patient anxiety, and often necessitating multiple imaging sessions.In recent years, various fusion imaging methods have been used to assess AM after ablation in HCC patients, including CT-CT image fusion \[8, 9\], MR-MR image fusion \[10, 11\], and contrast-enhanced ultrasound (CEUS)-CT/MR image fusion \[12, 13\]. However, fusion imaging techniques require high-quality preoperative images, and post-operative liver displacement and deformation due to tumour removal can make image registration difficult. Contrast-enhanced ultrasound (CEUS) is widely used in clinical practice due to its economic simplicity, lack of radiation, and ability to display lesion areas in real time \[14-16\]. Recently, fusion imaging based on 3D CEUS has been reported to show good accuracy in AM evaluation \[17-19\], but the assessment of AM for multiple ablations of multiple tumours remains uncertain.Therefore, the potential of CEUS for early assessment of AM should be further developed. Simultaneous-screen comparison contrast-enhanced ultrasound (SBS-CEUS) refers to the simultaneous comparison of arterial phase images before and after tumour ablation under the same settings of the ultrasound diagnostic instrument.Studies have shown \[20\] that SBS-CEUS has significant value in displaying liver lesions in difficult-to-visualise areas, but to date, no studies have systematically compared SBS-CEUS with CEUS in the assessment of AM. This retrospective study therefore compared the diagnostic accuracy of SBS-CEUS versus CEUS for early (1-3 days) assessment of the AM after MWA in patients with HCC.
Trial Details
NCT Number NCT07598331
Lead Sponsor The First Hospital of Jilin University
Conditions Side-by-side Contrast-enhanced Ultrasound, Hepatocellular Carcinoma (HCC)
Enrollment 106 participants
Start Date 2021-06-01
Primary Completion 2022-07-31 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-20